We conducted a retrospective descriptive study of a series of 31 consecutively presenting patients who had been implanted with the Vibrant Soundbridge middle ear hearing device. All implantations had been performed by the senior author. Three of these patients had undergone bilateral implantation, and 4 others had undergone subsequent explantation and reimplantation in response to known or suspected device failure, giving us a total of 34 ears and 38 implants. Our goal was to ascertain short-and longterm outcomes as measured by conventional audiometry (pure-tone average at 1 to 6 kHz) and long-term benefi t as defi ned by the use or nonuse of the device. We found that at the initial activation session 2 months postoperatively, the average hearing thresholds were within 3 dB of the preoperative thresholds in all 34 ears and all 38 implants. The mean short-term gain at activation in the 38 implants was 28.1 dB. Nineteen patients (20 ears) were available for long-term evaluation, with the length of follow-up ranging from less than 1 year to 11 years (mean: 7.3). Of these 20 ears, 9 demonstrated further gain (mean: 10.8 dB) despite any natural hearing deterioration; of the remaining 11 ears, gain was unchanged in 2, diminished in 7 (mean: -3.6 dB), and gain data were unavailable in 2. In the fi nal analysis, there were 20 user ears and 10 nonuser ears; 4 ears were lost to all follow-up. We conclude that direct-drive hearing with the Vibrant Soundbridge middle ear hearing device is benefi cial and provides sustained audiometric gain. Factors that have a signifi cant impact on patient use or nonuse include diffi culty in obtaining audiologic support and the direct and indirect costs of the device. Without audiologic or fi nancial support, some patients may choose to become nonusers and to either switch to conventional hearing aid amplifi cation or become apathetic about hearing improvement. Volume 89, Number 9 www.entjournal.com ■ E10 VIBRANT SOUNDBRIDGE IMPLANTABLE HEARING DEVICE: CRITICAL REVIEW AND SINGLE-SURGEON SHORT-AND LONG-TERM RESULTS * Explanted and reimplanted because of internal device failure. † Explanted and reimplanted because of suspected internal device failure.
Introduction
In 1996, Symphonix Devices, Inc., asked the senior author (C.M.L.) to evaluate direct vibration of the ossicular chain during surgery under local anesthesia to establish the feasibility of developing a wearable device for the treatment of sensorineural hearing loss. 1 The fi rst 4 Vibrant Soundbridge middle ear hearing devices with a fl oating mass transducer (FMT) were implanted in the United States by the senior author in 1996 and 1997. Since then, the senior author has performed this implantation on 27 other patients. This article details the results of implantation in these 31 consecutively presenting patients, whose follow-up ranged from less than 1 year to as long as 11 years.
Patients and methods
The Vibrant Soundbridge middle ear hearing device was implanted in 31 patients-19 men and 12 women, aged 28 to 74 years at presentation (mean: 56.0)-who desired an alternative to hearing aid amplifi cation and who met the audiometric criteria for device placement. These criteria included:
• adult patient with stable sensorineural hearing loss;
• a word recognition score of 50% or better on a recorded monosyllabic word test; and
• normal middle ear function and an absence of retrocochlear or central involvement.
All implantations were performed by the senior author between October 1996 and April 2007. All implants were placed in the poorer-hearing ear. Three of the 31 patients elected to have their contralateral ear implanted at a later date (patients 8, 21, and 23). In addition, 4 other patients underwent explantation and reimplantation in the same ear; the reasons for this were internal device failure in 3 cases (patients 3, 6, and 7) and suspected failure in 1 case (patient 4) (table 1) .
Some patients had been initially enrolled under a study protocol as part of a federal Food and Drug Administration (FDA) clinical trial, and others underwent implantation after the clinical trial had ended.
Hearing thresholds were measured in dB as mean pure-tone average (PTA) thresholds from 1 to 6 kHz. Three PTA values were analyzed: the preoperative value, the PTA obtained 2 months postoperatively at device activation, and the most recent follow-up value. For those patients who were unable to participate in audiometric follow-up, telephone follow-up was sought. Patients were interviewed to determine their degree of device use, and they were thus classifi ed as either users or nonusers. For nonusers, an effort was made to determine the reason for their lack of use.
Results
The average change in unaided hearing in the immediate postoperative period was within 3 dB of preoperative levels. The audiometric gain at activation ranged from 6 to 51 dB (mean: 28.1) (table 2). There was correlation between the preoperative hearing level and the amount of gain at activation. Three of the 4 patients who underwent explantation had similar postoperative gains following reimplantation. One patient (patient 6) was upgraded from an analog processor to a digital processor at revision surgery, and she experienced a gain of 14 dB (table 2) .
Follow-up ranged from less than 1 year to 11 years (mean: 7.3). Of the 31 patients, 19 were available for follow-up (20 ears) and 12 were not (14 ears). Of the 20 ears available for follow-up, 18 were determined to be user ears and 2 were nonuser ears; of the 14 ears not available for comprehensive follow-up, 2 were determined to be user ears, 8 were nonuser ears, and 4 were lost to all follow-up. In all, 20 of the 34 ears were determined to be user ears.
In the 20 ears available for follow-up, an increase in gain between device activation and the most recent follow-up was seen in 9 ears (mean increase: 10.8 dB) despite any natural hearing deterioration. The greatest gains were seen in patient 1 (16 dB), patient 2 (31 dB), patient 3 (17 dB), and patient 19 (13 dB); in the other 5 ears, gain changes were minimal. Nine ears did not experience any gain during follow-up; of these, hearing was diminished in 7 (mean loss: 3.6 dB) and unchanged in 2. Gain data on 2 patients (patients 9 and 10) were not available (table 3) .
Of the 12 patients (14 ears) who were not available for follow-up, 8 were contacted and 4 were lost to any kind of follow-up. Of the 8 patients who were contacted, 4 were unavailable for audiometric testing because of travel circumstances (i.e., they had moved out of the area) and 4 did not commit to testing. Seven of these 8 patients (8 ears) were considered to be nonusers; the remaining patient did use the device bilaterally (patient 23), but only as a backup to hearing aids.
Of the 20 users, all but 3 wore a hearing aid in their contralateral ear. Almost all of the nonusers, including those who were lost to audiometric follow-up testing but who were contacted for interviews, wore bilateral hearing aids.
The reported change in gain was measured from the time of device activation to the most recent follow-up rather than from some specifi c time subsequent to activation. One could argue that acclimation to the device alone might produce higher gain scores, but this is unknown. However, the mean gain at activation in the 38 ears and the mean gain at the most recent follow-up in the 18 evaluable ears differed by only 3.3 dB (table 4) . While follow-up data refl ect only 52.6% of the total ears implanted, they do indicate a sustained gain.
Discussion
Direct drive of the ossicular chain for the treatment of sensorineural hearing loss is not a new concept. [2] [3] [4] [5] Prior to human implantation, Gan et al used single-point laser Doppler interferometry techniques in both bench and temporal bone studies on a magnetic implant-electromagnetic coil and an FMT demonstrating excellent stapes displacements over the frequency ranges of 250 to 8,000 Hz. 6 Ball et al studied the FMT with scanning laser Doppler vibrometry in order to obtain three-dimensional data from various placements on the ossicular chain. 7 The transducer is capable of producing sound pressure level equivalents greater than 115 dB in fresh temporal bones that are attached to the incus. It is the active element of the Vibrant Soundbridge device.
As reported by Tjellström et al, 5 patients underwent an acute human trial with a modifi cation of the FMT during surgery for conductive hearing losses under local anesthesia. 1 The FMT was attached to the incus long process, and the patient was given an audiometer response switch to indicate an appropriate response to auditory stimulus. Other placement locations were tested, including the footplate, which gave a good response. The senior author was involved in a phase III clinical trial of the Vibrant Soundbridge device, which was implanted in 53 patients at 10 centers throughout the U.S. 8 Patients were followed for 5 months after surgery. Patient satisfaction, performance, and preference values were signifi cantly greater after Vibrant Soundbridge implantation, as was functional gain across all test frequencies.
That study demonstrated both safety (residual hearing and immittance) and effi cacy (functional gain, word recognition, and self-assessment). Both feedback and the occlusion effect that is seen with conventional hearing aids were virtually eliminated. Aided speech recognition with the Soundbridge device and with hearing aids was comparable, and there was no change in residual hearing.
A recent multicenter study at 19 tertiary care referral hospitals in France, which included 125 patients implanted between 1997 and 2000, yielded follow-up data on 77. 9 Follow-up ranged from 5 to 8 years (mean: 6). Functional gain was measured from 500 to 4,000 Hz, with maximal gain at 2,000 Hz. No signifi cant change in gain occurred from the 3-month level seen at activation time.
The present study involved all patients who had been implanted by a single surgeon, including some who had participated in the previously mentioned phase III clinical trial. 8 During the clinical trial, no patient was lost to follow-up through 5 months, and the results were outstanding. However, the unanswered question in this present study is, If the initial results from the phase III trial were so good, why was there such a high loss of follow-up and a reluctance to continue programming? This is a major consideration for future direct-drive ossicular implants after regulatory clinical trials.
A disturbing trend was the loss to audiologic follow-up despite similarities in preoperative hearing loss, age, sex, and gain at the initial activation. Geographic location was one factor but others are unknown. Five patients with The earlier patients in the present study seem to have had the best followup and results. Others simply could not be located. The loss of follow-up was surprising given that the initial activation results were satisfactory for these patients. There seems to be a variable disconnect between initial activation and long-term use and follow-up.
Among the advantages of the Vibrant Soundbridge device are that ossicular continuity is maintained and there were no complications from surgery in this series. There were 4 device failures in the fi rst 7 patients. Over the longer term, however, the technology was good and reliable. Unfortunately, it is cost-prohibitive to many who are good candidates. Third-party denial of reimbursement continues to be a major factor in the U.S., unlike in Europe. Recent steps undertaken by the manufacturer, including refi ning the indication to include those patients who are medically unable to use a conventional hearing aid, may improve future reimbursement.
In conclusion, the present study has shown that direct-drive hearing with the Vibrant Soundbridge device is benefi cial and provides sustained audiometric gain without having any impact on residual hearing. The device has improved hearing in patients who were otherwise unhappy with or unable to successfully benefi t from conventional amplifi cation. The patients' reports of subjective improvements and changes in quality of life have been encouraging. However, despite such promising results, a lack of access to widespread local audiologic support and the burden of the direct and indirect device costs can have a signifi cant negative impact on its use and patient follow-up. Without continued support and involvement with a Soundbridge implant center, some patients may choose to become nonusers, return to conventional hearing aid amplifi cation, or exhibit apathy toward their hearing. An analogy might be made to the early days of cochlear implantation and the necessity of a strong relationship and close followup with the implant center to maximize programming and device use. Careful preoperative counseling in this regard seems very important as the fi eld of implantable middle ear direct-drive prostheses develops. 
